Advertisement

Macrophage-Mediated Cytotoxicity

  • Penelope J. Duerksen-Hughes
  • Linda R. Gooding

Abstract

Macrophages are among the most versatile and multifunctional of cells. Their phagocytic ability is an essential part of the nonspecific immune defense against microorganisms, and macrophages are also required for the specific immune responses, mediated by T and B cells, to occur. In addition, macrophages manufacture and release a wide variety of substances with many different functions (for a review, see Nathan, 1987). Perhaps the most remarkable thing about macrophages is their ability to differentiate between normal and transformed cells, and between normal and infected cells, and to selectively leave the normal cells unharmed while killing the transformed or infected cells (Fidler and Schroit, 1988). Thus, macrophages not only can discriminate between self and nonself, but also can often distinguish between normal and abnormal self. This chapter will examine the cytotoxic activity of macrophages against transformed and infected cells both in vivo and in vitro.

Keywords

Tumor Necrosis Factor Nitric Oxide Murine Macrophage Muramyl Dipeptide Venezuelan Equine Encephalitis Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abramson SL, Gallin JI (1990): IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol 144: 625–630Google Scholar
  2. Adams DO (1980): Effector mechanisms of cytolytically activated macrophages. I. Secretion of neutral proteases and effect of protease inhibitors. J Immunol 124: 286–292Google Scholar
  3. Adams DO, Hamilton TA (1984): The cell biology of macrophage activation. Annu Rev Immunol 2: 283–318Google Scholar
  4. Adams DO, Hamilton TA (1987): Molecular transductional mechanisms by which IFN-y and other signals regulate macrophage development. Immunol Rev 97: 5–27Google Scholar
  5. Adams DO, Johnson WJ (1982): Activation of murine mononuclear phagocytes for destroying tumor cells: Analysis of effector mechanisms and development. Adv Exp Med Biol 155: 707–720Google Scholar
  6. Adams DO, Nathan CF (1983): Molecular mechanisms in tumor cell-killing by activated macrophages. Immunol Today 4: 166–170Google Scholar
  7. Adams LB, Franzblau SG, Vavrin Z, Hibbs JB, Jr, Krahenbuhl JL (1991): L-Arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae. J Immunol 147: 1642–1646Google Scholar
  8. Adams LB, Hibbs JB, Taintor RR, Krahanbuhl JL (1990): Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii: Role for synthesis of inorganic nitrogen oxides from L-arginine. J Immunol 144: 2725–2729Google Scholar
  9. Adams DO, Johnson WJ, Fiorito E, Nathan CF (1981): Hydrogen peroxide and cytolytic factor can interact synergistically in effecting cytolysis of neoplastic targets. J Immunol 127: 1973–1977Google Scholar
  10. Adams DO, Kao K-J, Farb R, Pizzo SV (1980): Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral pro-teases. J Immunol 124: 293–300Google Scholar
  11. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN (1985): Human tumor necrosis factor: Production, purification and characterization. J Biol Chem 260: 2345–2354Google Scholar
  12. Allison AC, (1974): On the role of mononuclear phagocytes in immunity against viruses. Prog Med Virol 18: 15–31Google Scholar
  13. Amber IJ, Hibbs JB, Jr, Parker CJ, Johnson BB, Taintor RR, Vavrin Z (1991): Activated macrophage conditioned medium: Identification of the soluble factors inducing cytotoxicity and the L-arginine dependent effector mechanism. J Leukocyte Biol 49: 610–620Google Scholar
  14. Bakouche O, Brown D, Lachman LB (1987): Subcellular localization of human monocyte interleukin 1: Evidence for an inactive precursor molecule and a possible mechanism for IL-1 release. J Immunol 138: 4249–4255Google Scholar
  15. Bakouche O, Ichinose Y, Heicappell R, Fidler IJ, Lachman LB (1988): Plasma membrane-associated tumor necrosis factor: A non-integral membrane protein possibly bound to its own receptor. J Immunol 140: 1142–1147Google Scholar
  16. Beutler B, Cerami A (1986): Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320: 584–588Google Scholar
  17. Beutler B, Cerami A (1989): The biology of cachectin/TNF—a primary mediator of the host response. Annu Rev Immunol 7: 625–655Google Scholar
  18. Bigazzi PE, Yoshida T, Ward PA, Cohen S (1975): Production of lymphokine-like factors (cytokines) by Simian virus 40-infected and Simian virus 40-transformed cells. Am J Pathol 80: 69–77Google Scholar
  19. Bucana C, Hoyer LC, Hobbs B, Breesman S, McDaniel M, Hanna MG, Jr (1976): Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells. Cancer Res 36: 4444–4458Google Scholar
  20. Bucana CD, Hoyer LC, Schroit AJ, Kleinerman E, Fidler IJ (1983): Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro. Am J Pathol 112: 101 - I11Google Scholar
  21. Chapes SK, Gooding LR (1985): Evidence for the involvement of cytolytic macrophages in rejection of SV40-induced tumors. J Immunol 135: 2192–2198Google Scholar
  22. Chedid L, Carelli L, Audibert F (1979): Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J Reticuloendothel Soc. 26: 631Google Scholar
  23. Chen MJ, Holskin B, Strickler J, Gorniak J, Clark MA, Johnson PJ, Mitcho M, Shalloway D (1987): Induction by E 1 A oncogene expression of cellular susceptibility to lysis by TNF. Nature 330: 581–583Google Scholar
  24. Chensue SW, Remick DG, Shmyr-Forsch C, Beals TF, Kunkel SL (1988): Immunohistochemical demonstration of cytoplasmic and membrane-associated tumor necrosis factor in murine macrophages. Am J Pathol 133: 564–572Google Scholar
  25. Cianciolo G, Hunter J, Silva J, Haskill JS, Snyderman R (1981): Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the p,s(E) structural protein of retroviruses. J Clin Invest 68: 831–844Google Scholar
  26. Clark RA, Klebanoff SJ (1979): Role of the myeloperoxidase-H,O2-halide system in concanavalin A-induced tumor cell killing by human neutrophils. J Immunol 122: 2605–2610Google Scholar
  27. Clark RA, Szot S (1981): The myeloperoxidase-hydrogen peroxide-halide system as effector of neutrophilmediated tumor cell cytotoxicity. J Immunol 126: 1295–1301Google Scholar
  28. Cohen MS, Taffet SM, Adams DO (1982): The relationship between competence for secretion of H2O, and completion of tumor cytotoxicity by BCG-elicited murine macrophages. J Immunol 128: 1781–1785Google Scholar
  29. Conlon PJ, Grabstein KH, Alpert A, Prickett KS, Hopp TP, Gillis S (1987): Localization of human mononuclear cell interleukin 1. J Immunol 139: 98–102Google Scholar
  30. Cook JL, Hibbs JB, Lewis AM (1980): Resistance of simian virus 40-transformed hamster cells to the cytolytic effect of activated macrophages: A possible factor in species-specific viral oncogenicity. Proc Natl Acad Sci USA 77: 6773–6777Google Scholar
  31. Cook JL, Hibbs JB, Lewis AM, Jr (1982): DNA virus-transformed hamster cell-host effector cell interactions: Level of resistance to cytolysis correlated with turnorigenicity. Int J Cancer 30: 795–803Google Scholar
  32. Cook JL, May DL, Lewis AM, Jr, Walker TA (1987): Adenovirus EIA gene induction of susceptibility to lysis by natural killer cells and activated macrophages in infected rodent cells. J Virol 61: 3510–3520Google Scholar
  33. Cook JL, May DL, Wilson BA, Holskin B, Chen M-J, Shalloway D, Walker TA (1989): Role of tumor necrosis factor-x in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages. J Immunol 142: 4527–4534Google Scholar
  34. Decker T, Lohmann-Matthes M-L, Gifford GE (1987): Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 138: 957–962Google Scholar
  35. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ, Srimal S (1990): Macrophage deactivating factor and transforming growth factors-βl, β2, and -β3 inhibit induction of macrophage nitrogen oxide synthesis by I FN-y. J Immunol 145: 940–944Google Scholar
  36. Ding AH, Nathan CF, Stuehr DJ (1988): Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407–2412Google Scholar
  37. Ding A, Wright SD, Nathan C (1987): Activation of mouse peritoneal macrophages by monoclonal antibodies to Mac-1 (complement receptor type 3). J Exp Med 165: 733–749Google Scholar
  38. Dinney CPN, Bucana CD, Utsugi T, Fidler IJ, von Eschenbach AC, Killion JJ (1991): Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362. Cancer Res 51: 3741–3747Google Scholar
  39. Drapier J-C, Hibbs JB, Jr. (1986): Murine cytotoxic activated macrophages inhibit aconitase in tumor cells: Inhibition involves the iron-sulfur prosthetic group and is reversible. J Clin Invest 78: 790–797Google Scholar
  40. Drapier J-C, Hibbs JB, Jr (1988): Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 140: 2829–2838Google Scholar
  41. Drapier J-C, Wietzerbin J, Hibbs JB, Jr (1988): Interferon-y and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 18: 1587–1592Google Scholar
  42. Duerksen-Hughes P, Wold WSM, Gooding LR (1989): Adenovirus EIA renders infected cells sensitive to cytolysis by tumor necrosis factor. J Immunol 143: 4193–4200Google Scholar
  43. Evans R, Alexander P (1972): Mechanism of immunologically specific killing of tumour cells by macrophages. Nature 236: 168–170Google Scholar
  44. Feinman R, Henriksen-DeStefano D, Tsujimoto M, Vicek J (1987): Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J Immunol 138: 635–640Google Scholar
  45. Fidler IJ (1978): Recognition and destruction of target cells by tumoricidal macrophages. Isr J Med Sci 14: 177–191Google Scholar
  46. Fidler IJ (1985): Macrophages and metastasis—a biological approach to cancer therapy: Presidential Address. Cancer Res 5: 4714–4726Google Scholar
  47. Fidler IJ, Kleinerman ES (1984): Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 2: 937–943Google Scholar
  48. Fidler IJ, Schroit AJ (1988): Recognition and destruction of neoplastic cells by activated macrophages: Discrimination of altered self. Biochim Biophys Acta 948: 151–173Google Scholar
  49. Fidler IJ, Fan D, Ichinose Y (1989): Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. Invasion Metastasis 9: 75–88Google Scholar
  50. Fidler IJ, Roblin RO, Poste G (1978): In vitro tumoricidal activity of macrophages against virus-transformed lines with temperature-dependent transformed phenotypic characteristics. Cell Immunol 38: 131–146Google Scholar
  51. Fidler IJ, Sone S, Fogler WE, Barnes ZL (1981): Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78: 1680–1684Google Scholar
  52. Fiers W (1991): Tumor necrosis factor: Characterization at the molecular, cellular and in vivo level. FEBS Lett 285: 199–212Google Scholar
  53. Figueiredo F, Uhing RJ, Okonogi K, Gettys TW, Johnson SP, Adams DO, Prpic V (1990): Activation of the cAMP cascade inhibits an early event involved in murine macrophage la expression. J Biol Chem 265: 12317–12323Google Scholar
  54. Gifford GE, Lohmann-Matthes M-L (1986): Requirement for the continual presence of lipopolysaccharide for production of tumor necrosis factor by thioglycollate-induced peritoneal murine macrophages. Mt J Cancer 38: 135–137Google Scholar
  55. Ginsberg HS, Lundholm-Beauchamp U, Horswood RL, Pernis B, Wold WSM, Chanock RM, Prince GA (1989): Role of early region 3 (E3) in the pathogenesis of adenovirus disease. Proc Natl Acad Sci USA 86: 3823–3827Google Scholar
  56. Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, Prince GA (1991): A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 88: 1651–1655Google Scholar
  57. Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WSM (1988): A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 53: 341–346Google Scholar
  58. Granger DL, Hibbs JB, Jr, Perfect JR, Durack DT (1988): Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J Clin Invest 81: 1129–1236Google Scholar
  59. Granger DL, Hibbs JB, Jr, Perfect JR, Durack DT (1990): Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest 85: 264–273Google Scholar
  60. Green SJ, Meltzer MS, Hibbs JB, Jr, Nacy CA (1990): Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 144: 278–283Google Scholar
  61. Haak-Frendscho M, Wynn TA, Czuprynski CJ, Paulnock D (1990): Transforming growth factor-β inhibits activation of macrophage cell line RAW 264.7 for cell killing. Clin Exp Immunol 82: 404–410Google Scholar
  62. Haberland ME, Tannenbaum CS, Williams RE, Adams DO, Hamilton TA (1989): Role of the maleyl-albumin receptor in activation of murine peritoneal macrophages in vitro. J Immunol 142: 855–862Google Scholar
  63. Hahn T, Toker L, Budilovsky S, Aderka D, Eshhar Z, Wallach D (1985): Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. Proc Natl Acad Sci USA 82: 3814–3818Google Scholar
  64. Hamilton TA, Adams DO (1987): Molecular mechanisms of signal transduction in macrophages. Immunol Today 8: 151–158Google Scholar
  65. Hamilton TA, Jansen MM, Somers SD, Adams DO (1986): Effects of bacterial lipopolysaccharide on protein synthesis in murine peritoneal macrophages: Relationship to activation for macrophage tumoricidal function. J Cell Physiol 128: 9–17Google Scholar
  66. Hammond ME, Roblin RO, Dvorak AM, Selvaggio SS, Black PH, Dvorak HF (1974): MIF-like activity in simian virus 40-transformed 3T3 fibroblast cultures. Science 185: 955–957Google Scholar
  67. Hasday JD, Shah EM, Lieberman AP (1990): Macrophage tumor necrosis factor—a release is induced by contact with some tumors. J Immunol 145: 371–379Google Scholar
  68. Hibbs JB, Jr (1974a): Heterocytolysis by macrophages activated by Bacillus Calmette-Guer in: Lysosome exocytosis into tumor cells. Science 184: 468–471Google Scholar
  69. Hibbs JB, Jr (1974b): Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J Natl Cancer Inst 53: 1487–1492Google Scholar
  70. Hibbs JB, Jr, Taintor RR, Vavrin Z (1984): Iron depletion: Possible cause of tumor cell cytotoxicity induced by activated macrophages. Biochem Biophys Res Commun 123: 716–723Google Scholar
  71. Hibbs JB, Jr, Taintor RR, Vavrin Z (1987a): Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235: 473–476Google Scholar
  72. Hibbs JB, Jr, Taintor RR, Vavrin Z, Rachlin EM (1988): Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157: 87–94Google Scholar
  73. Hibbs JB, Jr, Vavrin Z, Taintor RR (1987b): L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 138: 550–565Google Scholar
  74. Higuchi M, Higashi N, Taki H, Osawa T (1990): Cytolytic mechanisms of activated macrophages: Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J Immunol 144: 1425–1431Google Scholar
  75. Hirsch MS, Zisman B, Allison AC (1970): Macrophages and age-dependent resistance to herpes simplex virus in mice. J Immunol 104: 1160–1165Google Scholar
  76. Ichinose Y, Bakouche O, Tsao JY, Fidler IJ (1988): Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated macrophages lyse both. J Immunol 141: 512–518Google Scholar
  77. James SL, Glavin J (1989): Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J Immunol 143: 4208–4212Google Scholar
  78. Johnson WJ, Pizzo SV, Imber MJ, Adams DO (1982): Receptors for maleylated proteins regulate secretion of neutral proteases by murine macrophages. science 218: 574–576Google Scholar
  79. Johnston, RB, Jr, Kitagawa S (1985): Molecular basis for the enhanced respiratory burst of activated macrophages. Fed Proc 44, 2927–2932Google Scholar
  80. Jones EY, Stuart DI, Walker NPC (1989): Structure of tumour necrosis factor. Nature 338: 225–228Google Scholar
  81. Jue D-M, Sherry B, Luedke C, Manogue KR, Cerami A (1990): Processing of newly synthesized cachectin/ tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry 29: 8371–8377Google Scholar
  82. Kitagaua S, Johnston RB (1986): Deactivation of the respiratory burst in activated macrophages: Evidence for alteration of signal transduction. J Immunol 136: 2605–2612Google Scholar
  83. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ (1989): Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49: 4665–4670Google Scholar
  84. Kleinerman ES, Zicht R, Sarin PS, Gallo RC, Fidler IJ (1984): Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from y-interferon by a human T-cell leukemia virus-positive cell line. Cancer Res 44: 4470–4475Google Scholar
  85. Klostergaard J, Leroux MF (1989): L-Arginine independent macrophage tumor cytotoxicity. Biochem Biophys Res Commun 165: 1262–1266Google Scholar
  86. Klostergaard J, Leroux ME, Hung M-C (1991): Cellular models of macrophage tumoricidal effector mechanisms in vitro: Characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro. J Immunol 147: 2802–2808Google Scholar
  87. Klostergaard J, Stoltje PA, Kull FC, Jr (1990): Tumoricidal effector mechanisms of murine BCG-activated macrophages: Role of TNF in conjugation-dependent and conjugation-independent pathways. J Leukocyte Biol 48: 220–228Google Scholar
  88. Koff WC, Fidler IJ, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES (1984): Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science 224: 1007–1009Google Scholar
  89. Koff WC, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES (1985): Human monocyte-mediated cytotoxicity against herpes simplex virus-infected cells: Activation of cytotoxic monocytes by free and liposome-encapsulated lymphokines. J Leukocyte Biol 37: 461–472Google Scholar
  90. Koff WC, Showalter SD, Seniff DA, Hampar B (1983): Lysis of Herpesvirus-infected cells by macrophages activated with free or liposome-encapsulated lymphokine produced by a murine T cell hybridoma. Infect. Immun. 42: 1067–1072Google Scholar
  91. Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988): A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45–53Google Scholar
  92. Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER (1985): Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci USA 82: 1204–1208Google Scholar
  93. Kurt-Jones EA, Virgin HW IV, Unanue ER (1986): In vivo and in vitro expression of macrophage membrane interleukin 1 in response to soluble and particulate stimuli. J Immunol 137: 10–14Google Scholar
  94. Kwon NS, Nathan CF, Gilker C, Griffith OW, Matthews DE, Stuehr DJ (1990): L-Citrulline production from L-arginine by macrophage nitric oxide synthase: The ureido oxygen derives from dioxygen. J Biol Chem 265: 13442–13445Google Scholar
  95. Kwon NS, Nathan CF, Stuehr DJ (1989): Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 264: 20496–20501Google Scholar
  96. Lachman LB, Dinarello CA, Llansa ND, Fidler IJ (1986): Natural and recombinant human interleukin 1-/3 is cytotoxic for human melanoma cells. J Immunol 136: 3098–3102Google Scholar
  97. Lambert LE, Paulnock DM (1989): Differential induction of activation markers in macrophage cell lines by interferon-y. Cell Immunol 120: 401–418Google Scholar
  98. Lancaster JR, Jr, Hibbs JB, Jr (1990): EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. Proc Natl Acad Sci USA 87: 1223–1227Google Scholar
  99. Laster SM, Gooding LR (1990): Evidence that a target-derived soluble factor is necessary for the selective lysis of SV40-transformed fibroblasts by activated mouse macrophages. J Immunol 144: 1438–1443Google Scholar
  100. Laster SM, Wood JG, Gooding LR (1988): Target-induced changes in macrophage migration may explain differences in lytic sensitivity among simian virus 40-transformed fibroblasts. J Immunol 141: 221–227Google Scholar
  101. LeBlanc PA (1989): Macrophage activation for cytolysis of virally infected target cells. J Leukocyte Biol 45: 345–352Google Scholar
  102. Lefkowitz DL, Mone J, Mills K, Hsieh T-C, Lefkowitz SS (1989): Peroxidases enhance macrophage-mediated cytotoxicity via induction of tumor necrosis factor. Proc Soc Exp Biol Med 190: 144–149Google Scholar
  103. Lehn M, Weiser WY, Engelhorn S, Gillis S, Remold HG (1989): IL-4 inhibits H,O2 production and antileishmanial capacity of’ human cultured monomediated by IFN-y. J Immunol 143: 3020–3024Google Scholar
  104. Letvin NL, Kauffman RS, Finberg R (1982): An adherent cell lyses virus-infected targets: Characterization, activation, and fine specificity of the cytotoxic cell. J Immunol 129: 2396–2401Google Scholar
  105. Leu RW, Leu NR, Shannon BJ, Fast DJ (1991): IFN-y differentially modulates the susceptibility of L1210 and P815 tumor targets for macrophage-mediated cytotoxicity: Role of macrophage-target interaction coupled to nitric oxide generation, but independent of tumor necrosis factor production. J Immunol 147: 1816–1822Google Scholar
  106. Liew FY, Li Y, Millott S (1990a): Tumor necrosis factor-s synergizes with IFN-y in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145: 4306–4310Google Scholar
  107. Liew FY, Millott S, Parkinson C, Palmer RMJ, Moncada S (1990b): Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144: 4794–4797Google Scholar
  108. Luettig B, Decker T, Lohmann-Matthes M-L (1989): Evidence for the existence of two forms of membrane tumor necrosis factor: An integral protein and a molecule attached to its receptor. J Immunol 143: 4034–4038Google Scholar
  109. Maddox DE, Shibata S, Goldstein IJ (1982): Stimulated macrophages express a new glycoprotein receptor reactive with Griffonia simplicifolia 1-B4 isolectin. Proc Natl Acad Sci USA 79: 166–170Google Scholar
  110. Marino PA, Adams DO (1980a): Interaction of Bacillus Calmette-Guerin-activated macrophages and neoplastic cells in vitro: I. Conditions of binding and its selectivity. Cell Immunol 54: 11–25Google Scholar
  111. Marino PA, Adams DO (1980b): Interaction of Bacillus Calmette-Guerin-activated macrophages and neoplastic cells in vitro: II. The relationship of selective binding to cytolysis. Cell Immunol 54: 26–35Google Scholar
  112. Marino PA, Adams DO (1982): The capacity of activated murine macrophages for augmented binding of neo-plastic cells: Analysis of induction by lymphokine containing MAF and kinetics of the reaction. J Immunol 128: 2816–2823Google Scholar
  113. Marietta MA (1989): Nitric oxide: Biosynthesis and biological significance. Trends Biol Sci 14: 488–492Google Scholar
  114. Marietta MA, Yoon PS, Iyengar R, Leaf CD, Whishnok JS (1988): Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate. Biochemistry 27: 8706–8711Google Scholar
  115. Matsushima K, Taguchi M, Kovacs EJ, Young HA, Oppenheim JJ (1986): Intracellular localization of human monocyte associated interleukin 1 (IL-1) activity and release of biologically active IL-1 from monocytes by trypsin and plasmin. J Immunol 136: 2883–2891Google Scholar
  116. Meltzer MS (1981): Macrophage activation for tumor cytotoxicity: Characterization of priming and triggering signals during lymphokine activation. J Immunol 127: 179–183Google Scholar
  117. Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Moller A, Jacobsen H, Kirchner H (1986): Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 323: 816–819Google Scholar
  118. Mogensen SC (1985): Genetic aspects of macrophage involvement in natural resistance to virus infections. Immunol Letts 11: 219–224Google Scholar
  119. Moncada S, Palmer RMJ, Higgs EA (1988): The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 12: 365–372Google Scholar
  120. Morahan PS, Connor JR, Leary KR (1985): Viruses and the versatile macrophage. Br Med Bull 41: 15–21Google Scholar
  121. Mosselmans R, Hepburn A, Dumont JE, Fiers W, Galand P (1988): Endocytic pathway of recombinant murine tumor necrosis factor in L-929 cells. J Immunol 141: 3096–3100Google Scholar
  122. Nathan CF (1987): Secretory products of macrophages. J Clin Invest 79: 319–326Google Scholar
  123. Nathan CF, Brukner LH, Silverstein SC, Cohn ZA (1979a): Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med 149: 84–99Google Scholar
  124. Nathan CF, Silverstein SC, Brukner LH, Cohn ZA (1979b): Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med 149: 100–113Google Scholar
  125. Nestel FP, Carson PR, Wiltrout RH, Kerbel RS (1984): Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: Characterization of activated macrophage-and natural killer cell-resistant tumor variants. J Natl Cancer Inst 73: 483–490Google Scholar
  126. Nü A, Fidler IJ (1990): The incubation of human blood monocytes with tumor necrosis factor-a leads to lysis of tumor necrosis factor-sensitive but not resistant tumor cells. Lymphokine Res 9: 113–124Google Scholar
  127. Nissen-Meyer J, Austgulen R, Espevik T (1987): Comparison of recombinant tumor necrosis factor and the monocyte-derived cytotoxic factor involved in monocyte-mediated cytotoxicity. Cancer Res 47: 2251–2258Google Scholar
  128. Nong Y-H, Titus RG, Ribeiro JMC, Remold HG (1989): Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol 143: 45–49Google Scholar
  129. Okubo A, Sone S, Tanaka M, Ogura T (1989): Membrane-associated interleukin la as a mediator of tumor cell killing by human blood monocytes fixed with paraformaldehyde. Cancer Res 49: 265–270Google Scholar
  130. Old LJ (1985): Tumor necrosis factor (TNF). Science 230: 630–632Google Scholar
  131. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ (1985): Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 135: 3962–3968Google Scholar
  132. Pace JL, Russell SW (1981): Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J Immunol 126: 1863–1867Google Scholar
  133. Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW (1983): Recombinant mouse y interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 130: 2011–2013Google Scholar
  134. Paulnock DM, Lambert LE (1990): Identification and characterization of monoclonal antibodies specific for macrophages at intermediate stages in the tumoricidal activation pathway. J Immunol 144: 765–773Google Scholar
  135. Paya CV, Kenmotsu N, Schoon RA, Liebson PJ (1988): Tumor necrosis factor and lymphotoxin secretion by human natural killer cells leads to antiviral cytotoxicity. J Immunol 141: 1989–1995Google Scholar
  136. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M (1990): A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63: 251–258Google Scholar
  137. Philip R, Epstein LB (1986): Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin1. Nature 323: 86–89Google Scholar
  138. Poste G, Kirsh R, Fogler WE, Fidler IJ (1979): Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res 39: 881–892Google Scholar
  139. Raz A, Inbar M, Goldman R (1977): A differential interaction in vitro of mouse macrophages with normal lymphocytes and malignant lymphoma cells. Eur J Cancer 13: 605–615Google Scholar
  140. Reidarson TH, Granger GA, Klostergaard J (1982): Inducible macrophage cytotoxins. II. Tumor lysis mechanism involving target cell-binding proteases. J Natl Cancer Inst 69: 889–894Google Scholar
  141. Reynolds CW, Reichardt D, Henkart M, Millard P, Henkart P (1987): Inhibition of NK and ADCC activity by antibodies against purified cytoplasmic granules from rat LGL tumors. J Leukocyte Biol 42: 642–652Google Scholar
  142. Ruff MR, Gifford GE (1981): Tumor necrosis factor. Lymphokines 2: 235–272Google Scholar
  143. Russell SW, Gillespie GY, Pace JL (1980): Evidence for mononuclear phagocytes in solid neoplasms and appraisal of their nonspecific cytotoxic capabilities. Contemp Top Immunobiol 10: 143–166Google Scholar
  144. Russell SW, Pace JL, Varesio L, Akporiaye E, Blasi E, Celado A, Schreiber RD, Schultz RM, Stevenson AP, Stewart CC, Stewart SJ (1986): Comparison of five short-term assays that measure nonspecific cytotoxicity mediated to tumor cells, by activated macrophages. J Leukocyte Biol 40: 801–813Google Scholar
  145. Sasada M, Pabst MJ, Johnston RB, Jr (1983): Activation of mouse peritoneal macrophages by lipopolysaccharide alters the kinetic parameters of the superoxide-producing NADPH oxidase. J Biol Chem 258: 9631–9635Google Scholar
  146. Savill J, Dransfield I, Hogg N, Haslett C (1990): Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 343: 170–173Google Scholar
  147. Schroit AJ, Madsen JW, Tanaka Y (1985): In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 260: 5131–5138Google Scholar
  148. Schroit AJ, Tanaka Y, Madsen J, Fidler IJ (1984): The recognition of red blood cells by macrophages: Role of phosphatidylserine and possible implications of membrane phospholipid asymmetry. Biol Cell 51: 227–238Google Scholar
  149. Schultz RM, Pavlidis NA, Stylos WA, Chirigas MA (1978): Regulation of macrophage tumoricidal function: A role for prostaglandins of the E series. Science 202: 320–321Google Scholar
  150. Sebaldt RJ, Prpic V, Hollenbach PW, Adams DO, Uhing RJ (1990): IFN-y potentiates the accumulation of diacylglycerol in murine macrophages. J Immunol 145: 684–689Google Scholar
  151. Shepard HM, Lewis GD (1988): Resistance of tumor cells to tumor necrosis factor. J Clin Immunol 8: 333–341Google Scholar
  152. Shiver JW, Henkart PA (1991): A noncytotoxic mast cell tumor line exhibits potent IgE-dependent cytotoxicity after transfection with the cytolysin/perforin gene. Cell 64: 1175–1181Google Scholar
  153. Slivka A, Buglio AFL, Weiss SJ (1980): A potential role for hypochlorous acid in granulocyte-mediated tumor cell cytotoxicity. Blood 55: 347–350Google Scholar
  154. Smith RA, Baglioni C (1987): The active form of tumor necrosis factor is a trimer. J Biol Chem 262: 6951–6954Google Scholar
  155. Snyderman R, Pike MC (1976): An inhibitor of macrophage chemotaxis produced by neoplasms. Science 192: 370–372Google Scholar
  156. Somers SD, Hamilton TA, Adams DO (1987): Maleylated bovine serum albumin triggers cytolytic function in selected populations of primed murine macrophages. J Immunol 139: 1361–1368Google Scholar
  157. Somers SD, Mastin JP, Adams DO (1983): The binding of tumor cells by murine mononuclear phagocytes can be divided into two qualitatively distinct types. J Immunol 131: 2086–2093Google Scholar
  158. Somers SD, Whisnant CC, Adams DO (1986): Quantification of the strength of cell-cell adhesion: The capture of tumor cells by activated murine macrophages proceeds through two distinct stages. J Immunol 136: 1490–1496Google Scholar
  159. Srimal S, Nathan C (1990): Purification of macrophage deactivating factor. J Exp Med 171: 1347–1361Google Scholar
  160. Stott EJ, Probert M, Thomas LH (1975): Cytotoxicity of alveolar macrophages for virus-infected cells. Nature 255: 710–712Google Scholar
  161. Stuehr DJ, Nathan CF (1989): Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169: 1543–1555Google Scholar
  162. Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF (1991a): Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: An FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci USA 88: 7773–7777Google Scholar
  163. Stuehr DJ, Fasehun OA, Kwon NS, Gross SS, Gonzalez JA, Levi R, Nathan CF (1991b): Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J 5: 98–103Google Scholar
  164. Stuehr DJ, Gross SS, Sakuma I, Levi R, Nathan CF (1989a): Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp Med 169: 1011–1020Google Scholar
  165. Stuehr DJ, Kwon NS, Gross SS, Thiel BA, Levi R, Nathan CF (1989b): Synthesis of nitrogen oxides from L-arginine by macrophage cytosol: Requirement for inducible and constitutive components. Biochem Biophys Res Commun 161: 420–426Google Scholar
  166. Stuehr DJ, Kwon NS, Nathan CF (1990): FAD and GSH participate in macrophage synthesis of nitric oxide. Biophys Biochem Res Commun 168: 558–565Google Scholar
  167. Stuehr DJ, Kwon NS, Nathan CF, Griffith OW, Feldman PL, Wiseman J (1991c): N“-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine”. J Biol Chem 266: 6259–6263Google Scholar
  168. Suttles J, Carruth LM, Mizel SB (1990): Detection of IL-1a and IL-1ß in the supernatants of paraformaldehyde-treated human monocytes: Evidence against a membrane form of IL-l. J Immunol 144: 170–174Google Scholar
  169. Szuro-Sudol A, Nathan CF (1982): Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med 156: 945–961Google Scholar
  170. Taffet SM, Russell SW (1981): Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J Immunol 126: 424–427Google Scholar
  171. Tanaka Y, Schroit AJ (1983): Insertion of fluorescent phosphatidylserine into the plasma membrane of red blood cells: Recognition by autologous macrophages. J Biol Chem 258: 11335–11343Google Scholar
  172. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Jr, Goeddel DV (1991): The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 88: 9292–9296Google Scholar
  173. Tayeh MA, Marletta MA (1989): Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate: Tetrahydrobiopterin is required as a cofactor. J Biol Chem 264: 19654–19658Google Scholar
  174. Tsunawaki S, Nathan CF (1986): Macrophage deactivation: Altered kinetic properties of superoxide-producing enzyme after exposure to tumor cell-conditioned medium. J Exp Med 164: 1319–1331Google Scholar
  175. Tsunawaki S, Sporn M, Ding A, Nathan C (1988): Deactivation of macrophages by transforming growth factor-β. Nature 334: 260–262Google Scholar
  176. Tsunawaki S, Sporn M, Nathan C (1989): Comparison of transforming growth factor-β and a macrophage deactivating polypeptide from tumor cells: Differences in antigenicity and mechanism of action. J Immunol 142: 3462–3468Google Scholar
  177. Uhing RJ, Adams DO (1989): Molecular events in the activation of murine macrophages. Agents Actions 26: 9–14Google Scholar
  178. Urban JL, Schreiber H (1983): Selection of macrophage-resistant progressor tumor variants by the normal host: Requirement for concomitant T-cell mediated immunity. J Exp Med 157: 642–656Google Scholar
  179. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H (1986): Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA 83: 5233–5237Google Scholar
  180. Utsugi T, Fidler IJ (1991): Prostaglandin E2 does not inhibit tumoricidal activity of mouse macrophages against adherent tumor cells. J Immunol 146: 2066–2071Google Scholar
  181. Utsugi T, Dinney CPN, Killion JJ, Fidler IJ (1991a): In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CPT 31362. Cancer Immunol Immunother 33: 375–381Google Scholar
  182. Utsugi T, Nii A, Fan D, Pak CC, Denkins Y, van Hoogevest P, Fidler IJ (199lb): Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Immunol Immunother 33: 285–292Google Scholar
  183. Wei RQ, Lefkowitz SS, Lefkowitz DL, Everse J (1986): Activation of macrophages by peroxidases. Proc Soc Exp Biol Med 182: 515–521Google Scholar
  184. Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ (1989/1990): Macrophages and cancer. Cancer Metastasis Rev 8: 319–351Google Scholar
  185. Wilson KM, Siegal G, Lord EM (1989): Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages. Cell Immunol 123: 158–165Google Scholar
  186. Wiltrout RH, Brunda MJ, Holden HT (1982): Variation in selectivity of tumor cell cytolysis by murine macrophages, macrophage-like cell lines and NK cells. Int J Cancer 30: 335–342Google Scholar
  187. Wong GHW, Goeddel DV (1986): Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature 323: 819–822Google Scholar
  188. Wong GHW, Elwell JH, Oberley LW, Goeddel DV (1989): Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58: 923–931Google Scholar
  189. Yu S-F, Koerner TJ, Adams DO (1990): Gene regulation in macrophage activation: Differential regulation of genes encoding for tumor necrosis factor, interleukin-1, JE, and KC by interferon-y and lipopolysaccharide. J Leukocyte Biol 48: 412–419Google Scholar
  190. Ziegler-Heitbrock HWL, Moller A, Linke RP, Haas JG, Rieber EP, Riethmuller G (1986): Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res 46: 5947–5952Google Scholar

Copyright information

© Birkhäuser Boston 1993

Authors and Affiliations

  • Penelope J. Duerksen-Hughes
  • Linda R. Gooding

There are no affiliations available

Personalised recommendations